43 results about "Reproductive disease" patented technology

The present invention provides a vaccine which protects pigs from a virus and / or an infectious agent causing a porcine respiratory and reproductive disease, a method of protecting a pig from a disease caused by a virus and / or an infectious agent which causes a respiratory and reproductive disease, a method of producing a vaccine against a virus and / or an infectious agent causing a porcine reproductive and respiratory disease, and a biologically pure sample of a virus and / or infectious agent associated with a porcine respiratory and reproductive disease, particularly the Iowa strain of porcine reproductive and respiratory syndrome virus (PRRSV), and an isolated polynucleotide which is at least 90% homologous with a polynucleotide obtained from the genome of a virus and / or infectious agent which causes a porcine respiratory and reproductive disease.

A compound represented by the general formula (I-a):[wherein R1a and R2a each means hydrogen, lower cycloalkyl, lower alkyl, etc.; R3a means hydrogen, lower cycloalkyl, lower alkyl, etc.; R4a and R5a each means lower alkyl, lower cycloalkyl, etc. or R4a and R5a are bonded to each other to form lower cycloalkylidene; and R6a means lower alkyl, lower haloalkyl, etc.]. This compound functions as an LCE inhibitor and is useful as a therapeutic agent for various circulatory diseases, nervous diseases, metabolic diseases, reproductive diseases, digestive tract diseases, neoplasm, infectious diseases, etc.

The present invention relates to combination vaccines and methods for treating or preventing diseases or disorders in an animal caused by infection by Bovine Viral Diarrhea Virus (BVDV) Types 1 and 2, Bovine Herpes Virus Type-1 (BHV-1), Bovine Respiratory Syncytial Virus (BRSV), Parainfluenza Virus (PI3), Campylobacter fetus, Leptospira canicola, Leptospira grippotyphosa, Leptospira hardj-prajitno, Leptospira icterohaemmorrhagiae, Leptospira hardjo-bovis and Leptospira pomona by administering to the animal an effective amount of a combination vaccine. The combination vaccine can be a whole or partial cell inactivated or modified live preparation.

The invention discloses an application of a compound NSC-156529 in preparation of a T-type calcium channel antagonist. The compound inhibits the T-type calcium channel current in a dose-dependent manner through non-G-protein and non-Akt dependent ways. The T-type calcium channel antagonist drug containing the NSC-156529 structure can be constructed to be used for treating or preventing neuropsychiatric diseases (such as primary tremor, prosopalgia, cancer pain, schizophrenia, epilepsy, Parkinson's disease and depression) and reproductive diseases (such as varicocele infertility and sexual dysfunction) related to T-type calcium channel dysfunction.

The present inventors found out four kinds of fragments (42 kD, 36 kD, 32 kD, 27 kD) by forcibly expressing vasohibin in a vascular endothelial cell. The present inventors analyzed those fragments and, as a result, found out low molecular weight vasohibin which has an anti-angiogenic activity. The low molecular weight vasohibin is useful as a therapeutic agent for various diseases such as a vascular disease associated with angiogenesis, an inflammatory disease, an entoptic neovascular disease, a reproductive disease, a central nervous system disease and cancer and the like. In addition, the low molecular weight vasohibin is also useful as a marker for angiogenesis.

The present invention relates to methods for treating or preventing diseases or disorders in a pregnant cow and calf nursing a pregnant cow caused by infection by Bovine Viral Diarrhea Virus (BVDV) Types 1 and 2, Bovine Herpes Virus Type-1 (BHV-1), Bovine Respiratory Syncytial Virus (BRSV), Parainfluenza Virus (PIV3), Campylobacter fetus, Leptospira canicola, Leptospira grippotyphosa, Leptospira hardj-prajitno, Leptospira icterohaemmorrhagiae, Leptospira hardjo-bovis and Leptospira pomona by administering to the animal an effective amount of a safe modified live viral combination vaccine further combined with a multivalent bacterin vaccine.

The invention discloses a CMKLR1 antagonistic polypeptide and derivatives and application thereof, and particularly relates to analogs of the CMKLR1 antagonistic polypeptide shown in sequences SEQ IDNO.1-17 and derivatives thereof. The derivatives of the binding peptide are products obtained after conventional modification of amino terminals or carboxyl terminals on CMKLR1 binding peptide amino acid side chain groups and CMKLR1 antagonistic polypeptide fragments. The binding peptide and the derivatives thereof can be bonded with CMKLR1 in vitro, and by blocking the bond of chemerin and CMKLR1, cAMP concentration increase is promoted, calcium influx caused by chemerin is inhibited and cell chemotaxis caused by chemerin is inhibited. Besides, proliferation of ovarian cancer cells can be inhibited, the cell cycle is blocked, apoptosis of the ovarian cancer cells is promoted, and effective small-molecular treatment drugs are provided for female reproductive diseases such as ovarian cancer.

Novel proteins of the present invention that have an organic anion transport activity are useful as, for example, a diagnostic marker for kidney diseases, liver diseases, pancreas diseases, immunological diseases associated with thymus failures, reproductive diseases, digestive diseases, spleen diseases, cancer, respiratory diseases, myelitis, diabetes, hypertension, reperfusion injury following ischemia, retinitis, central nervous diseases, skin diseases, thyroid hormone-associated diseases, etc. Compounds that promote or inhibit the activity of the above protein, which are obtained by a screening method using the protein, can be used as, for example, prophylactic / therapeutic agents for the above-described diseases.

The invention discloses a GPR1 antagonistic polypeptide and a derivative and application thereof and particularly relates to a GPR1 antagonistic polypeptide shown in SEQ ID No.1-25 and a derivative thereof. The derivative of the binding peptide is a product obtained in the mode that conventional modification is conducted on a GPR1 binding peptide amino acid side chain group and an amino terminal or a carboxyl terminal of a GPR1 antagonistic polypeptide fragment or a product obtained in the mode that a label for detection or purification of polypeptide or protein is linked to the GPR1 antagonistic polypeptide. The binding peptide and the derivative thereof can be combined with GPR1 in vitro, by stopping combination of chemerin and GPR1, increase of the cAMP concentration is promoted, the (Ca2+) influx caused by chemerin is inhibited, proliferation of breast cancer cells can be inhibited, the cell cycle of the breast cancer cells is blocked, apoptosis of the breast cancer cells is promoted, effective micromolecule treatment drugs are provided for female reproductive diseases such as breast cancer, and the GPR1 antagonistic polypeptide can be widely applied in the fields of medicine and biology.

The invention discloses a cow delivery monitor, which belongs to monitors. Its structure includes a monitoring built-in body, a handle frame and a controller. The monitoring built-in body cooperates with the handle frame, and the monitoring built-in body is connected with the controller. , a support column and a pressure sensor, the support member is arranged on the upper part of the support column, the support member includes a plurality of elastic support claws uniformly arranged along the circumferential direction of the support column, the pressure sensor is arranged on the upper surface of one of the elastic support claws, the pressure sensor and the control The device is connected, and the lower part of the support column is inserted into the handle frame. The invention has the function of sending a signal through the pressure sensor and transmitting the signal to the controller, so that the management personnel of the cattle farm can easily and accurately obtain which cow is about to give birth and the time of delivery, and avoid economic losses caused by dystocia and unclear blood registration of calves The occurrence of the situation; prevention of infection caused by placing foreign objects on the cow's vagina, and promotion of postpartum discharge of the placenta, avoiding or reducing the occurrence of postpartum reproductive diseases and other characteristics.

The invention relates to the technical field of medical treatment, in particular to a fumigation device for the reproductive medicine department and a pharmaceutical composition used by the fumigationdevice. The fumigation device comprises a seat plate, a supporting plate, a uniform fumigation mechanism, a liquefied water treatment mechanism and a dustproof cover, wherein the side face of the bottom of the seat plate is welded with the top of the supporting plate, the uniform fumigation mechanism and the liquefied water treatment mechanism are both connected in the middle of the seat plate, the right side of the dustproof cover is movably connected with the right side of the top of the seat plate through a hinge, and the composition is composed of common carpesium fruits, common cnidium fruits, radix astragali, the rhizome of chuanxiong, radix paeoniae alba and wormwood in proportion. The fumigation device has the advantages that the uniform fumigation mechanism is guided into the female genitalia, so that the effect of directly fumigating the inner portion of the female genitalia is achieved, female reproductive diseases are treated by directly reaching to the lesion, a traditional Chinese medicine composition rectification solution with functions of diminishing inflammation, killing bacteria and clearing dump is taken as fumigation solution, compared with western medicine, the side effects are smaller, and the important drug property is milder, and the fumigation device is more suitable for the treatment of the female reproductive diseases.

The invention discloses a CMKLR1 antagonistic polypeptide and its derivatives and applications, specifically related to the sequence of SEQ ID No.1‑24 and its derivatives, the derivatives of the binding peptide are CMKLR1 binding peptide amino acid side chain group, CMKLR1 The product obtained by conventional modification of the amino-terminal or carboxyl-terminal of the antagonistic polypeptide fragment, or the product obtained by linking a tag for polypeptide or protein detection or purification on the CMKLR1 antagonistic polypeptide; the binding peptide and its derivatives can bind CMKLR1 in vitro , by blocking the combination of chemerin / RvE1 and CMKLR1, it promotes the increase of cAMP concentration, inhibits the calcium influx caused by chemerin, inhibits the cell chemotaxis caused by chemerin, and can inhibit the proliferation of ovarian cancer cells and promote the apoptosis of ovarian cancer cells. Small molecule drugs provide effective treatments for female reproductive diseases such as ovarian cancer.